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Abstract
Background: Dexamethasone is an antiemetic alternative to ondansetron. We aimed to compare the effects of
dexamethasone and ondansetron in preventing postoperative nausea and vomiting (PONV) in patients undergoing
laparoscopic surgery.
Methods: We searched PubMed, Embase, Medline and Cochrane Library (from inception to July 2014) for eligible
studies. The primary outcome was the incidence of PONV during the first 24 h after surgery. The secondary
outcomes included PONV in the early postoperative stage (0–6 h), PONV in the late postoperative stage (6–24 h),
and the postoperative anti-emetics used at both stages. We calculated pooled risk ratios (RR) and 95 % CIs using
random- and fixed-effects models.
Results: Seven trials involving 608 patients were included in this meta-analysis, which found that dexamethasone
had a comparable effectiveness in preventing PONV (RR, 0.91; 95 % CI, 0.73-1.13; P = 0.39) with that of ondansetron
within 24 h of laparoscopic surgery, with no evidence of heterogeneity among the studies (I2 = 0 %; P = 0.71). In
the early postoperative stage (0–6 h), ondansetron was better at decreasing PONV than dexamethasone (RR, 1.71;
95 % CI, 1.05-2.77; P = 0.03), while in the late postoperative stage (6–24 h), dexamethasone was more effective in
preventing PONV than ondansetron (RR, 0.51; 95 % CI, 0.27-0.93; P = 0.03). There was no significant difference in
the postoperative anti-emetics used (RR, 0.90; 95 % CI, 0.67-1.19; P = 0.45).
Conclusions: Dexamethasone was as effective and as safe as ondansetron in preventing PONV. Dexamethasone
should be encouraged as an alternative to ondansetron for preventing PONV in patients undergoing laparoscopic
surgery.
Background
Postoperative nausea and vomiting (PONV) is a common
distressing symptom in patients undergoing laparoscopic
surgery and can contribute to anxiety, dehydration, meta-
bolic abnormality, wound disruption, delayed recovery
and other issues [1]. The incidence of PONV varies from
20 to 80 %, and it is an economic and social burden.
Ondansetron is a selective 5-HT3 receptor antagonist,
that exhibits an anti-emetic action by antagonizing
vomiting signals in the afferent pathway from the
stomach or small intestine and solitary tract nucleus,
and is effective at preventing PONV [2, 3], however the
high cost of this drug has prevented it from being
widely used. Dexamethasone, a corticosteroid, was first
reported as an effective anti-emetic agent in patients
undergoing cancer chemotherapy in 1981 [4, 5]. Wang
et al. [6] confirmed that dexamethasone is most effect-
ive when it is administered at the induction rather than
at the termination of anaesthesia. However, the mechan-
ism underlying the anti-emetic effects of dexamethasone is
still unknown. It may be involved in central inhibition of
prostaglandin synthesis, or it may cause a decrease in
serotonin turnover in the central nervous system [5, 7, 8].
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Today, cost-benefit analyses have become an important
factor when considering what drugs to use as prophylactic
antiemetics. The cost-to-benefit ratio for the patient was
much higher in the ondansetron group than in the
dexamethasone group [9]. However, it has not been estab-
lished whether dexamethasone is a cost-effective alternative
to ondansetron in the prevention of PONV in patients
undergoing laparoscopic surgery. It is highly necessary to
conduct a meta-analysis to assess the results of the
currently published studies on this topic. Therefore, we
performed a systematic review to compare the efficacy
of dexamethasone with that of ondansetron.
Methods
This systematic review was carried out according to the
guidelines of the preferred reporting items for system-
atic reviews and meta-analyses (PRISMA) [10]. We pro-
spectively registered our system review at PROSPERO.
(Registration number: CRD420140013064).
Data sources and search strategy
PubMed, Embase, Medline and Cochrane Library data-
bases were searched from inception to July, 2014 for rele-
vant studies that investigated the differences in the anti-
emetic effects of dexamethasone and ondansetron. The
following search terms were used: Dexamethasone,
Hexadecadrol, Methylfluorprednisolone, Decameth, “Foy
Brand of Dexamethasone”, Decaspray, “Merck Brand of
Dexamethasone”, Dexasone, “ICN Brand of Dexametha-
sone”, Dexpak, “ECR Brand of Dexamethasone”, Maxidex,
“Alcon Brand of Dexamethasone”, Millicorten, Oradexon,
Decaject, “Merz Brand 1 of Dexamethasone”, “Decaject
L.A.”, “Decaject-L.A.”, “Merz Brand 2 of Dexametha-
sone”, Hexadrol, Ondansetron, “Ondansetron, (+,-)-Iso-
mer”, “Ondansetron, (R)-Isomer”, “Ondansetron, (S)-
Isomer”, “GR-38032F”, “GR 38032F”, “GR 38032F”, Zofran,
“Ondansetron Hydrochloride”, “Hydrochloride, Ondanse-
tron”, “Ondansetron Monohydrochloride Dihydrate”,
“Dihydrate, Ondansetron Monohydrochloride”, “Monohy-
drochloride Dihydrate, Ondansetron”, “Ondansetron
Monohydrochloride”, “Monohydrochloride, Ondansetron”,
SN 307, “SN-307”, “Laparoscopy”, Laparoscopies, Perito-
neoscopy, Peritoneoscopies, Celioscopy, Celioscopies, “Sur-
gical Procedures, Laparoscopic”, “Laparoscopic Surgical
Procedure”, “Surgical Procedure, Laparoscopic”, “Proced-
ure, Laparoscopic Surgical”, “Procedures, Laparoscopic Sur-
gical”, “Surgery, Laparoscopic”, “Laparoscopic Surgery”,
“Laparoscopic Surgeries”, “Surgeries, Laparoscopic”, “Lap-
aroscopic Surgical Procedures”, PONV, vomiting, emesis
and nausea. A manual search of the reference sections of
the included trials, published meta-analyses, and pertinent
review articles was also conducted to identify additional
relevant articles. If duplicated data were presented in
several publications, only the most recent, largest or most
complete study was included in this meta-analysis.
Study selection
The original studies included in this meta-analysis were
based on PICOS (patient, intervention, comparison, out-
comes and study design) as follows: (a) P: American Society
of Anesthesiology (ASA) I/II grade adult patients undergo-
ing laparoscopic surgery; (b) I and C: dexamethasone and
ondansetron respectively; (c) O: reporting the incidence of
PONV; (d) S: only randomized controlled trials (RCTs).
Only articles published in English were included. Patients
who had a history of nausea or vomiting or who had been
given H2 blockers 48 h prior to the operation were ex-
cluded. Patients with the following characteristics were also
excluded: history of motion sickness, facing kidney prob-
lems with a high level of BUN or Cr, history of allergy to
the study drug, body mass index (BMI) > 35 and being
pregnant or menstruating.
Data extraction
The characteristics of the patients (number of patients,
ASA rating, age, gender, type of surgery and anaesthesia)
and the trial designs (intervention, follow-up duration
and reported outcomes) were also recorded. If the data
mentioned above were unavailable in the article, the cor-
responding authors were called upon to obtain the miss-
ing information. All data were independently extracted
using a standard data collection form by 2 reviewers
(XXW and FRH), then, the collected data were checked
and entered into Review Manager analysis software
(RevMan) Version 5.3. All discrepancies were reviewed
and a consensus was reached by discussion with a third
author (DBP). The reasons that studies were excluded
were recorded.
Assessment of study quality
A critical evaluation of the quality of the included studies
was performed by two reviewers (XXW and HJG) using a
5-point Jadad scale [11]. The main categories consisted of
the following five items: “Was the study described as ran-
domized?”, “Was the method used to obtain the sequence
of randomization described and appropriate (random num-
bers, computer-generated, etc.)?”, “Was the study described
as double-blind?”, “Was the method of double-blinding de-
scribed and appropriate (identical placebo, active placebo,
dummy, etc.)?”, and “Was there a description of with-
drawals and drop-outs?”. Scores of four and five indicated a
high methodological quality.
Assessment of risk of bias
Two reviewers (XXW and QZ) independently evaluated
the risk of bias according to the recommendations of the
Cochrane Collaboration [12]. The principal categories
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consisted of random sequence generation, allocation con-
cealment, blinding of participants and personnel, blinding
of outcome assessment, incomplete outcome data, selective
reporting and other bias. Each domain was measured as
“high risk”, “low risk”, or “unclear risk”. Namely, items
with sufficient and correct information were judgment
was “low risk”, and items that were reported incorrectly
were judgment as “high risk”. If the information of the
item was insufficient or unsanctioned, they were judged
as “unclear risk”. An “unclear risk” judgement was ap-
plied if the item was reported, but the risk of bias was
unknown. Discrepancies were resolved by a senior re-
viewer (DBP).
Statistical analysis
RR with 95 % CI was used as a common measure of the dif-
ference in the efficacy of dexamethasone and ondansetron
for prophylaxis of postoperative nausea and vomiting across
studies. The power analyses of the individual studies
(Power and Precision V4) and meta-analysis were all
conducted by Review Manager 5.3. I2 was used to esti-
mate statistical heterogeneity. When I2 <50 %, hetero-
geneity was considered present, and the fixed-effects
model was applied. Otherwise, the randomized-effects
model and sensitivity analysis were applied. Publica-
tion bias was evaluated by Egger’s test. A P value <0.05
was considered statistically significant.
The quality of evidence was evaluated by two re-
viewers (HWD and AGZ) using the GRADE system
(GRADEprofiler 3.6.1). RCTs were considered to have
high-quality evidence. However, this assessment could
be downgraded for five reasons: risk of bias, inconsist-
ency, indirectness, imprecision and publication bias.
Finally, there were four levels of evidence quality, namely
high, moderate, low and very low.
Results
Identification of eligible studies
A total of 184 potentially relevant abstracts were identi-
fied. After duplicates were removed, one hundred and
forty six unique abstracts remained. After reviewing the
abstracts, only ten publications met the inclusion criteria.
Three of them were excluded because of incomplete data.
Finally, the remaining seven studies [1, 13–18] were in-
cluded in the present meta-analysis. The search strategy
and study selection are presented in the flow diagram of
Fig. 1.
Fig. 1 Flow diagram of search strategy and study selection
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Study characteristics
The characteristics of all included studies are shown in
Table 1. All studies were published between 2003 and
2013. The sample sizes of the studies ranged from 40 to
160 (total 608). Drug preparations were administered
intravenously before surgery. All included studies were
randomized controlled trials and all reported PONV and
the rescue anti-emetics used. No significant side effects of
dexamethasone or ondansetron were observed in these
studies. The definition of PONV was only clearly stated in
two studies (Gautan B et al. and Ashwani khimar et al.).
Meta-analyses of primary outcomes
Postoperative nausea and vomiting (0–24 h)
The results are shown in Fig. 2 and Table 1. PONV within
24 h was studied in seven trials [1, 13–18]. Overall, the
rates of PONV in the dexamethasone and ondansetron
groups were 33.3 and 36.7 %, respectively. Dexamethasone
was not associated with a significant reduction in the inci-
dence of PONV (RR, 0.91; 95 % CI, 0.73-1.13; P = 0.39), but
no evidence of heterogeneity was observed among the
remaining studies (I2 = 0 %; P = 0.71).
Postoperative nausea and vomiting at different stages
Furthermore, we conducted a subgroup meta-analysis
based on the postoperative stage to explore the efficacy of
dexamethasone for the prevention of PONV compared
with that of ondansetron. Dexamethasone was not superior
to ondansetron in preventing PONV in the early postopera-
tive stage (0–6 h) (RR, 1.22, 95 % CI 0.87-1.73; P = 0.25),
but there was significant heterogeneity in these data among
the studies (I2 = 65 %; P = 0.02). After the exclusion of two
trials that did not have any occurrence of PONV in the late
postoperative stage (6–24 h), dexamethasone was found to
be superior to ondansetron in preventing PONV in the late
postoperative stage (RR, 0.51, 95 % CI, 0.27-0.93; P = 0.03),
and the heterogeneity among the studies was more moder-
ate for these data than for the data for the early postopera-
tive stage (I2 = 37 %; P = 0.20) (Fig. 3). Subsequently, a
sensitivity analysis was carried out to explore the po-
tential source of heterogeneity in the early postopera-
tive stage. As shown in Fig. 4, the results of Nita
D’souza et al. [1] were completely out of the range of
those of the other studies and this probably contrib-
uted to the observed heterogeneity. After excluding this
Table 1 Characteristics of trials included in systematic review
Study No. of patients
(dexamethasone/
ondansetron)
Patient characteristics Jadad score Type of anaesthesia Intra-abdominal
pressure
D’souza N et al. 61(30/31) Adult patients undergoing laparoscopic
gynaecologic surgery
4 General 10-14 mmHg
Ashwani K et al. 160(80/80) Adult patients undergoing laparoscopic
cholecystectomy
4 General None
Erhan Y et al. 40(20/20) Adult patients undergoing laparoscopic
cholecystectomy
4 General 12 mmHg
Gautan B et al. 95(47/48) Adult patients undergoing laparoscopic
cholecystectomy
5 General Below 15 mmHg
Aighanem SM et al. 120(60/60) Adult patients undergoing laparoscopic
cholecystectomy
5 General 10-16 cm of water
Mohammad E et al. 92(46/46) Adult patients undergoing laparoscopic
cholecystectomy
5 General Below 15 mmHg





Fig. 2 Forest plot of PONV within 24 h of surgery
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study, the results suggested that compared with dexa-
methasone, ondansetron was associated with a decreased
of incidence PONV (RR 1.71, 95 % CI, 1.05-2.77; P = 0.03).
Meta-analyses of secondary outcomes (0–24 h)
Figure 5 describes the postoperative anti-emetics used
within 24 h. The results of these studies suggested no
difference in the overall postoperative anti-emetics be-
tween the dexamethasone and ondansetron groups
(RR, 0.90, 95 % CI, 0.67-1.19; P = 0.45). Additionally,
no heterogeneity in any of the secondary outcomes was
observed (I2 = 0 %; P = 0.88).
Quality assessment and quality of evidence
This systematic review included 7 RCTs: the baseline
characteristics of patients were reported by all trials.
Only one trial mentioned the method of randomization
(Fig. 6).
This meta-analysis examined four outcomes: PONV
(0–24 h, 0–6 h and 6–24 h) and postoperative anti-
emetics (0–24 h). The quality of the evidence for each
outcome is presented in Table 2.
Power analysis
Although statistical results were presented in some studies,
a portion of the primary data was unavailable. The available
data were reassessed by a power analysis with an α level of
0.05 (Table 3). The power of the individual studies ranged
from 5.1 to 64 %. The power of the meta-analysis with re-
spect to PONV (0–24 h, 0–6 h and 6–24 h) and postopera-
tive anti-emetics (0–24 h) was 12.2, 17.9, 64 and 9.1 %,
respectively (Table 3).
Fig. 3 Forest plot of PONV at different stages
Fig. 4 Forest plot of Sensitivity Analysis in the early postoperative stage (0–6 h)
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Publication bias
Egger’s test did not reveal any significant difference with
respect to all outcomes. This result indicated that no
publication bias existed (t = 0.66, P = 0.537).
Discussion
This is the first meta-analysis to compare the efficacy of
dexamethasone with that of ondansetron in preventing
PONV after laparoscopic surgery. The pooled meta-
analysis of 7 RCTs using a fixed-effects model suggested
that there were no significant differences between dexa-
methasone and ondansetron in regards to the incidence of
PONV or postoperative anti-emetics used during the first
24 h after laparoscopic surgery. Ondansetron was more
effective at decreasing PONV in the early postopera-
tive stage (0–6 h), while dexamethasone was more
effective at decreasing PONV in the late postoperative
stage (6–24 h).
Glucocorticoids bind to intracellular glucocorticoid re-
ceptors, and exert their effects via gene transcription
[19]. As changes to both gene expression and protein
synthesis take time, most effects of corticosteroids are
not instantaneous, rather, they only become apparent
after several hours. Therefore, glucocorticoids usually
take 1–2 h to have biologic effects, and this also depends
on the route of administration [20]. This may explain
why dexamethasone was found to significantly decrease
PONV in the late postoperative stage (6–24 h) rather
than in the early postoperative stage (0–6 h) in our data
analysis. Interestingly, Thomas and Jones [21] found a
failure of prophylaxis during the first 3 h after laparo-
scopic surgery in 28.3 % of patients who had received
Fig. 5 Forest plot of anti-emetics used within 24 h postoperatively
Fig. 6 a Risk of bias grap. b Risk of bias summary
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Table 2 GRADE evidence profile
No. of patients Effect Quality











Serious None 101/303(33.3 %) 112/305(36.7 %) RR 0.91(0.72-1.12) 33 fewer per 1000 (from
103 fewer to 44 more)
MODERATE






Serious None 47/163(28.8 %) 39/165(23.6 %) RR 1.25(0.84-1.76) 59 more per 1000 (from
38 fewer to 180 more)
MODERATE






Serious None 13/163(8 %) 26/165(15.8 %) RR 0.48(0.25-0.92) 82 fewer per 1000 (from
13 fewer to 118 more)
MODERATE






Serious None 65/303(21.5 %) 73/305(23.9 %) RR 0.89(0.64-1.19) 26 fewer per 1000 (from














dexamethasone compared to with 22 % of patients who
had received ondansetron. The late onset and prolonged
antiemetic efficacy of dexamethasone may be attributed
to its prolonged biological half-life (36–72 h) [22]. Ac-
cordingly, the timing of dexamethasone administration is
important. It is necessary to administrate dexamethasone
1–2 h preoperatively [23], especially for short surgical pro-
cedures. The findings of this meta-analysis depend on the
quality of the included primary trials. Despite the declar-
ation of randomization design, only one trial reported se-
quence generation, which might decrease the level of
evidence of this meta-analysis.
Based on the GRADE system, the qualities of outcomes
were all “moderate”, and evidence quality was degraded
owing to this imprecision. Only two studies clearly defined
PONV.
To assess the probability of correctly rejecting the null
hypothesis, a power analysis was performed. If H1 is true,
the power is 1-β. To guard against Type I error, α is typic-
ally set to 0.05, and to guard against Type II error, β is set
to 0.20 [24–26]. Thus, a power of more than 80 % is neces-
sary to reject the null hypothesis. In our meta-analysis, the
power was <80 %. Therefore, this meta-analysis did not
provide enough evidence on the effects of the study drugs
and more high level studies are required.
In our meta-analysis, the patients enrolled were quite
homogeneous. The studies all had Jadad scores of ≥ 4
and were of high quality. For all studies, a fixed-effects
model and test of heterogeneity between trials resulted
in an I2 value of (0.0 %) and a P of value (0.71), indicat-
ing no heterogeneity. The participants in all studies
were well matched (e.g., sex, age, ASA grade, adminis-
tration time, method of surgery/anaesthesia, et al.).
However, several limitations of this meta-analysis
should be taken into account. First, there was no gold
standard for the definition of PONV, resulting in pos-
sible overestimation or underestimation of the true ef-
fect of dexamethasone administration compared with
that of ondansetron. Furthermore, this meta-analysis was
based on studies published in the English language, which
may have generated bias. Next, the sample sizes of the stud-
ied individual trials were small or moderate. The over dif-
ference in the incidence of PONV (0–24 h) was not
different between the dexamethasone and ondansetron
groups, which may be due to the small sample size and lack
of evidence. Finally, we selected published studies, and
many studies were not registered on clinical trial data-
bases. Data from unpublished literature could be missing,
which would lead to bias. However, the Egger’s test result
suggested that no publication bias existed.
Nonetheless, our study provides useful evidence for fu-
ture studies on PONV. Different drugs (dexamethasone
and ondansetron) have different working times and half-
lives, so attention should be paid to the time-effect relation-
ship of these drugs. Further studies may also focus on the
safety of dexamethasone, as long-term corticosteroid
administration causes side effects such as wound healing
delays, infection, and adrenal suppression. Moreover, in
our study, the drugs were only compared when they were
used in patients undergoing laparoscopic surgery, so other
medical situations in which these drugs are used should
also be studied.
Conclusion
In summary, dexamethasone was equally effective and as
safe as ondansetron in preventing PONV. However, in
the late postoperative stage (6–24 h), dexamethasone
probably has an advantage over ondansetron. Consider-
ing the limitations of this study, our findings should be
considered with caution, and large-scale studies are
needed to confirm our findings.
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Ashwani K et al. 10.30 % NA NA 10.30 %
Gautan B et al. 5.10 % 57 % 45.30 % 5.50 %
Mohammad E et al. 6.90 % 42.40 % 64 % 8.50 %
Yuksek MS et al. 24.20 % 24.20 % NA 14.10 %
D’souza N et al. 28.70 % 28.70 % NA 23.60 %
Alghanem SM et al. 5.20 % NA NA 7.10 %
Erhan Y et al. 10.50 % 20.20 % 18 % 6.60 %
All studies 12.20 % 17.90 % 64 % 9.10 %
NA Not available
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